Worldwide Thermostable Vaccines and Thermostable Biologics Industry to 2035 - Featuring Allena Pharmaceuticals, Amarillo Biosciences and Vaxart Among Others
Friday, February 11, 2022
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- The "Thermostable Vaccines and Thermostable Biologics Market by Type of Molecule, Target Indications, Type of Therapy, Key Players, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report features an extensive study of the current market landscape and future opportunity for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles.
However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability.
Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.
At present, several biopharmaceutical companies and clinical research institutes are engaged in the development of thermostable vaccines and thermostable biologics, taking into consideration the rising global population, growing demand for vaccines and specific requirements of large-scale immunization initiatives.
Moreover, significant efforts are being put into the development of technologies / devices, which enables transition of conventional vaccines to thermostable vaccines. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in research in this domain, encouraging clinical trial results, and ongoing technological advancement, the thermostable vaccines and thermostable biologics market is anticipated to grow at a commendable pace in the mid to long-term.
Amongst other elements, the report includes:
-- An overview of thermostable vaccines and biologics market, featuring a
detailed analysis of pipeline molecules, based on several relevant
parameters, such as type of molecule, type of formulation, type of
manufacturing technology, trial phase (clinical, preclinical and
discovery), route of administration, type of storage conditions, type of
disease indication (Covid-19, diabetes and others), and target
therapeutic area (infectious diseases, metabolic disorders, and others).
It also includes information on the completed, ongoing and planned
clinical trials for thermostable vaccines and biologics, sponsored by
various industry players. It also provides insights on developer
landscape along with the analysis based on several parameters, including
year of establishment, company size, location of headquarters.
-- An insightful competitiveness analysis of thermostable vaccines and
biologics developers, taking into consideration the supplier strength
(based on expertise of the manufacturer), product portfolio strength,
portfolio diversity, and number of area(s) of application.
-- A detailed analysis of close to 150 peer-review, scientific articles
related to research on thermostable vaccines and biologics, such as year
of publication, type of publication focus area (therapeutic area),
impact factor, most popular author and most popular journals.
-- An analysis of the partnerships that have been inked by various
stakeholders engaged in the development of thermostable vaccines and
biologics, during the period 2015-2021, covering product development
agreements, research and development agreements, licensing agreements,
clinical trial agreement, licensing and manufacturing agreement, product
development and commercialization manufacturing agreements, joint
venture, product development and commercialization, acquisition and
other types of partnership deals.
-- An analysis of the investments made at various stages of development of
the companies engaged in this field, covering instances of debt
financing, equity investments, Secondary offerings, seed funding,
award/grant funding, post-IPO Debt, post-IPO Equity, private equity and
other types of funding deals.
-- Tabulated profiles of the key players providing thermostable vaccines
and biologics. Each profile includes an overview of the company,
thermostable product portfolio, recent developments, and an informed
future outlook.
One of the key objectives of the report was to estimate the future growth potential of thermostable vaccines and biologics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2035. For this purpose, we have segmented the future opportunity across the following market segments: Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry's growth.
Key Questions Answered
-- Who are the leading players engaged in the development of thermostable
vaccines and biologics?
-- Which are the key clinical conditions that can be treated by
thermostable vaccines and biologics?
-- What is the trend of investment in this industry?
-- Which partnership models are commonly adopted by stakeholders engaged in
the development of thermostable vaccines and biologics domain?
-- Which factors are likely to influence the evolution of this market?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Overview of Vaccines and Biologics
3.3. Classification of Vaccines Based on Type of Active Ingredient
3.4. Limitations of Conventional Vaccines
3.5. Thermostable Vaccines and Biologics
3.5.1. Thermostability of Marketed Vaccines
3.5.2. Common Routes of Administration for Thermostable Vaccines
3.5.2.1. Oral Route
3.5.2.2. Intranasal Route
3.5.2.3. Intradermal Route
3.5.2.4. Inhalation Route
3.5.2.5. Intramuscular Route
3.6. Value Propositions of Thermostable Vaccines
3.7. Future Perspectives
4. Market Landscape: Thermostable Vaccines and Biologics
4.1. Chapter Overview
4.2. Thermostable Vaccines and Biologics: Product Pipeline
4.2.1. Analysis by Type of Biologics
4.2.2. Analysis by Type of Formulation
4.2.3. Analysis by Type of Manufacturing Technologies
4.2.4. Analysis by Trial Phase
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Type of Storage Condition
4.2.7. Analysis by Disease Indication
4.2.8. Analysis by Therapeutic Area
4.3. Thermostable Vaccines and Biologics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Products
5. Thermostable Vaccines and Biologics Manufacturers in North America
5.1. Chapter Overview
5.2. Allena Pharmaceuticals
5.2.1. Company Overview
5.2.2. Allena Pharmaceutical: Thermostable Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Amarillo Biosciences
5.3.1. Company Overview
5.3.2. Amarillo Biosciences: Thermostable Product Portfolio
5.4. Vaxart
5.4.1. Company Overview
5.4.3. Vaxart: Thermostable Product Portfolio
5.4.4. Recent Developments and Future Outlook
6. Thermostable Vaccines and Biologics Manufacturers in Europe
6.1. Chapter Overview
6.2. Tiziana Life Sciences
6.2.1. Company Overview
6.2.2. Tiziana Life Sciences: Thermostable Product Portfolio
6.3. Diabetology (A Subsidiary of Proxima Concepts)
6.3.1. Company Overview
6.3.2. Diabetology (A Subsidiary of Proxima Concepts): Thermostable Product Portfolio
7. Thermostable Vaccines and Biologics Manufacturers in Asia-Pacific
7.1 Chapter Overview
7.2. Biocon
7.2.1. Company Overview
7.2.2. Biocon: Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Serum Institute of India
7.3.1. Company Overview
7.3.2. Serum Institute of India: Product Portfolio
7.3.3. Recent Developments and Future Outlook
8. Company Competitiveness Analysis
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions/Key Parameters
8.4. Competitiveness Analysis: Thermostable Vaccines Service Providers
8.4.1. Competitiveness Analysis: Companies Offering Thermostable Vaccines in North America
8.4.2. Competitiveness Analysis: Companies Offering Thermostable Vaccines in Europe
8.4.3. Competitiveness Analysis: Companies Offering Thermostable Vaccines in Asia-Pacific
9. Publication Analysis
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Thermostable Vaccines and Biologics: Publication Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Type of Publication
9.3.3. Analysis by Focus Area (Therapeutic Area)
9.3.4. Analysis by Impact Factor
9.3.5. Most Popular Authors: Analysis by Number of Publications
9.3.6. Most Popular Journals: Analysis by Number of Publications
10. Partnerships and Collaborations
10.1. Chapter Overview
10.2. Partnership Models
10.3. Thermostable Vaccines and Biologics: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type and Year of Partnership
10.3.4. Analysis by Type of Partner
10.3.5. Analysis by Year of Partnership and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.7.1. Analysis by Intracontinental and Intercontinental Agreement
11. Funding and Investment Analysis
11.1. Chapter Overview
11.2. Types of Funding Instances
11.3. Thermostable Vaccines and Biologics: Recent Funding Instances
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Instances
11.3.5 Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks
12. Market Sizing and Opportunity Analysis
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Key Assumptions and Forecast Methodology
12.4. Overall Thermostable Vaccines and Biologics Market, 2021-2035
12.5. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Molecule
12.6. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Indication
12.7. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Area
12.8. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Key Players
12.8. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Geographical Region
12.9. Product-Wise Sales Forecast
12.9.1. Rotasiil (Serum Institute of India)
12.9.1.1. Target Patient Population
12.9.1.2. Sales Forecast (Usd Million)
12.9.2. Vxa-A1.1(Vaxart)
12.9.2.1. Target Patient Population
12.9.2.2. Sales Forecast (Usd Million)
12.9.3. Vxa-Nvv-105 (Vaxart)
12.9.3.1. Target Patient Population
12.9.3.2. Sales Forecast (Usd Million)
12.9.4. Relaxoliase (Allena Pharmaceuticals)
12.9.4.1. Target Patient Population
12.9.4.2. Sales Forecast (Usd Million)
13. Conclusion
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
For more information about this report visit https://www.researchandmarkets.com/r/cr1zfv
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/worldwide-thermostable-vaccines-and-thermostable-biologics-industry-to-2035---featuring-allena-pharmaceuticals-amarillo-biosciences-and-vaxart-among-others-301478573.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
|
